Chengda Biological: It is expected that the net profit will decrease by 59.34%-63.98% compared to 2025.

Nanchang Biotech announced that it is expected to achieve a net profit attributable to the owners of the parent company of 1.23 billion to 1.39 billion yuan in the fiscal year 2025, a decrease of 2.03 billion to 2.19 billion yuan compared to the same period last year, a year-on-year decrease of 59.34% to 63.98%. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be 31.85 million to 47.77 million yuan, a decrease of 2.76 billion to 2.92 billion yuan compared to the same period last year, a year-on-year decrease of 85.25% to 90.16%.